Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease.
Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of its €580M collaboration with Bayer in endometriosis therapies, Evotec has agreed on a new partnership to develop kidney disease treatments that could be as big as €300M.
Both companies will contribute novel drug targets and their platforms to the effort and share responsibilities for the preclinical development of their drug candidates. In exchange for access to Evotec’s drug candidates and CureNephron pipeline for kidney disease treatments, Bayer will manage clinical development and commercialisation.
Depending on the outcome, Evotec could receive between €14M and €300M from the billion-euro giant, depending on the results of preclinical, clinical and sales milestones, plus royalties.
Chronic kidney disease is marked by progressive loss of renal function,